Takasaki, HirotakaTomita, NaotoMotomura, ShigekiSakai, RikaIshigatsubo, YoshiakiTsuchihashi, HitoshiYamamoto, WataruIshii, Yoshimi2026-05-072013-04Experimental and Clinical Transplantation, Cilt, 11, Sayı, 2, 2013 ss. 199-2021304-0855https://hdl.handle.net/11727/15020High-dose chemotherapy with autologous stem cell transplant is commonly used for diffuse large B-cell lymphoma that recurs after successful salvage chemotherapy. However, in patients in whom the disease recurs again, the prognosis is poor. A 40-year-old woman who underwent allogeneic stem cell transplant 4 years after autologous stem cell transplant developed recurrent diffuse large B-cell lymphoma 3 years after the initial autologous stem cell transplant. She then underwent reduced-intensity hematopoietic stem cell transplant from a human leukocyte antigen-matched, unrelated donor who was not the previous autologous stem cell transplant donor. She achieved a long survival (328 days after the reduced-intensity hematopoietic stem cell transplant and 1844 days after the first allogeneic transplant). A second allogenic transplant may provide survival benefits in a proportion of patients with malignant lymphoma recurring after allogeneic transplant, although careful consideration is required because of the high risk of treatment-related mortality with second allogenic transplant.enVasculopathyImmunosuppressionChronic rejectionAlloantibodiesCase Report1122146-8427